<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DAPSONE <img border="0" src="../images/pr.gif"/></span><br/>(dap'sone)<br/><span class="topboxtradename">Aczone, </span><span class="topboxtradename">Avlosulfon <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">DDS<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antileprosy (sulfone) agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg tablets; 5% gel</p>
<h1><a name="action">Actions</a></h1>
<p>Sulfone derivative chemically related to sulfonamides, with bacteriostatic and bactericidal activity similar to that group.
         Interferes with bacterial cell growth by competitive inhibition of folic acid synthesis by susceptible organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Spectrum of activity includes <i>Mycobacterium leprae</i> (Hansen's bacillus), <i>Mycobacterium tuberculosis,</i> and limited activity against <i>Pneumocystis carinii</i> and <i>Plasmodium</i>. Drug is effective against dapsone-sensitive multibacillary (borderline, borderline lepromatous, or lepromatous) leprosy,
         and dapsone-sensitive paucibacillary (indeterminate, tuberculoid, or borderline tuberculoid) leprosy. Resistant strains of
         initially susceptible <i>M. leprae</i> develop slowly in a stepwise fashion over periods of 524 y.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Drug of choice for treatment of all forms of leprosy (unless organism is shown to be dapsone resistant). Used in dapsone-sensitive
         multibacillary leprosy (with clofazimine and rifampin) and in dapsone-sensitive paucibacillary leprosy (with rifampin, clofazimine,
         or ethionamide). Also used prophylactically in contacts of patients with all forms of leprosy except tuberculoid and indeterminate
         leprosy. Used for treatment of dermatitis herpetiformis. Gel used for acne vulgaris.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Chemoprophylaxis of malaria (with pyrimethamine), systemic and discoid lupus erythematosus, pemphigus vulgaris, dermatosis
         (especially those associated with bullous eruptions, mucocutaneous lesions, inflammation or pustules); rheumatoid arthritis,
         allergic vasculitis; treatment of initial episodes of <i>P. carinii</i> pneumonia (with trimethoprim) in limited number of adults with AIDS.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sulfones or its derivatives; advanced renal amyloidosis, anemia, methemoglobin reductase deficiency. Safe
         use during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Chronic renal, hepatic, pulmonary, or cardiovascular disease, refractory anemias, albuminuria, G6PD deficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tuberculoid and Indeterminate-type Leprosy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg/d (with 6 mo of rifampin 600 mg/d) for a minimum of 3 y<br/><br/><span class="indicationtitle">Lepromatous and Borderline Lepromatous Leprosy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg/d for <img src="../images/special/greaterorequal.gif"/>10 y<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 12 mg/kg/d once daily in combination therapy (max: 100 mg/d)<br/><br/><span class="indicationtitle">Dermatitis Herpetiformis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg/d, may be increased to 300 mg/d if necessary (max: 500 mg/d)<br/><br/><span class="indicationtitle">Prophylaxis for Close Contacts of Patient with Multibacillary Leprosy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>, 6 mg 3 times/wk; <i>623 mo</i>, 12 mg 3 times/wk; <i>25 y</i>, 25 mg 3 times/wk; <i>612 y</i>, 25 mg/d<br/><br/><span class="indicationtitle">
<i>P. carinii</i> Pneumonia Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg b.i.d. or 100 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2 mg/kg once daily (max: 100 mg/d)<br/><br/><span class="indicationtitle">Acne</span><br/><span class="rdroute"></span> Apply pea-sized amount of gel to affected area b.i.d.<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to reduce possibility of GI distress.</li>
<li>Store in tightly covered, light-resistant containers at 15°30° C (59°86° F). Drug discoloration
            apparently does not indicate a chemical change.
         </li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Clean skin with soap and water before application.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (cutaneous reactions); erythema multiforme, exfoliative dermatitis, <span class="speceff-life">toxic epidermal necrolysis</span> [rare], allergic rhinitis, urticaria, fever, infectous mononucleosis-like syndrome. <span class="typehead">CNS:</span> Headache, nervousness, insomnia, vertigo; paresthesia, <span class="speceff-common">muscle weakness</span>. <span class="typehead"> CV:</span>  Tachycardia. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, abdominal pain; <span class="speceff-life">toxic hepatitis</span>, cholestatic jaundice (reversible with discontinuation of drug therapy); increased ALT, AST, LDH; hyperbilirubinemia. <span class="typehead">Hematologic:</span> In patient with or without G6PD deficiency; <span class="speceff-common">dose-related hemolysis,</span> Heinz body formation, <span class="speceff-common">methemoglobinemia with cyanosis,</span> hemolytic anemia; <span class="speceff-life">aplastic anemia</span> (rare), <span class="speceff-life">agranulocytosis</span>. <span class="typehead">Skin:</span> Drug-induced lupus erythematosus, phototoxicity. <span class="typehead">Special Senses:</span> Blurred vision, tinnitus. <span class="typehead">Other:</span> Male infertility; sulfone syndrome (fever, malaise, exfoliative dermatitis, hepatic necrosis with jaundice, lymphadenopathy,
      methemoglobinemia, anemia). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Activated charcoal</b> decreases dapsone absorption and enterohepatic circulation; <b>pyrimethamine,</b>
<b>trimethoprim</b> increase risk of adverse hematologic reactions; <b>rifampin</b> decreases dapsone levels 710 fold. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and nearly completely absorbed from GI tract. <span class="typehead">Peak:</span> 28 h. <span class="typehead">Distribution:</span> Distributed to all body tissues; high concentrations in kidney, liver, muscle, and skin; crosses placenta; distributed into
      breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span>  7085% excreted in urine; remainder excreted in feces; traces of drug may be found in body for 3 wk after discontinuation
      of repeated doses. <span class="typehead">Half-Life:</span> 2030 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness that may not appear for leprosy until after 36 mo of therapy. Skin lesions respond
            well; recovery from nerve involvement is usually limited.
         </li>
<li>Lab tests: Perform baseline then weekly CBC during the first month of therapy, at monthly intervals for at least 6 mo, and
            semiannually thereafter.
         </li>
<li>Determine periodic dapsone blood levels.</li>
<li>Perform liver function tests in patients who complain of malaise, fever, chills, anorexia, nausea, vomiting, and have jaundice.
            Dapsone therapy is usually suspended until etiology is identified.
         </li>
<li>Monitor severity of anemia. Nearly all patients demonstrate hemolysis. Manufacturer states that Hgb level is generally decreased
            by 12 g/dL; reticulocytes increase by 212%; RBC life span is shortened; and methemoglobinemia occurs in most
            patients receiving dapsone.
         </li>
<li>Monitor temperature during first few weeks of therapy. If fever is frequent or severe, leprosy reactional state should be
            ruled out. Reduction of or interruption of therapy may be sufficient for improvement.
         </li>
<li>Report cyanotic appearance or mucous membranes with brownish hue to physician as possible methemoglobinemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report symptoms of leprosy that do not improve within 3 mo or get worse to physician.</li>
<li>Report the appearance of a rash with bullous lesions around elbows and other joints promptly. Drug-induced or worsening skin
            lesions require withdrawal of dapsone.
         </li>
<li>Report symptoms of peripheral neuropathy with motor loss (muscle weakness) promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>